New drug targets brain inflammation in Alzheimer's

NCT ID NCT06745583

Recruiting now Symptom relief Sponsor: Elixiron Immunotherapeutics Inc. Source: ClinicalTrials.gov ↗

First seen May 14, 2026 · Last updated Jun 18, 2026 · Updated 11 times

Summary

This study tests a new drug called EI-1071 in 15 people with mild to severe Alzheimer's disease. The main goal is to see if the drug is safe and tolerable over 4 weeks. Researchers will also check if it reduces brain inflammation using special brain scans. Participants must have stable Alzheimer's symptoms and be on steady medications for at least 8 weeks before joining.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MILD, MODERATE, OR SEVERE ALZHEIMER'S DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Taipei Veterans General Hospital
RECRUITING

Taipei, 112, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••
Tri-Service General Hospital
RECRUITING

Taipei, 11490, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction follicular lymphoma neurodegenerative disease Neuroinflammatory Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MILD, MODERATE, OR SEVERE ALZHEIMER'S DISEASE